Analysts expect that Aratana Therapeutics Inc (NASDAQ:PETX) will post ($0.18) earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Aratana Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.21). Aratana Therapeutics posted earnings of ($0.34) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 47.1%. The business is expected to issue its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Aratana Therapeutics will report full-year earnings of ($0.61) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.51). For the next fiscal year, analysts forecast that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.26) to $0.21. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Aratana Therapeutics.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. The company had revenue of $10.46 million during the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%.
A number of brokerages recently issued reports on PETX. Stifel Nicolaus reissued a “hold” rating and set a $6.00 price objective on shares of Aratana Therapeutics in a report on Monday, December 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Zacks Investment Research raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. Credit Suisse Group reissued an “outperform” rating and set a $8.00 price objective (down previously from $9.00) on shares of Aratana Therapeutics in a report on Friday, March 16th. Finally, CL King raised Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Monday, March 12th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $8.68.
In other Aratana Therapeutics news, CEO Peter Steven St sold 19,367 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total value of $92,380.59. Following the sale, the chief executive officer now owns 672,259 shares of the company’s stock, valued at approximately $3,206,675.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Craig A. Tooman sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the completion of the sale, the insider now directly owns 75,024 shares in the company, valued at approximately $395,376.48. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new stake in shares of Aratana Therapeutics in the 4th quarter valued at about $110,000. Millennium Management LLC purchased a new stake in shares of Aratana Therapeutics in the 4th quarter valued at about $3,267,000. Ellington Management Group LLC purchased a new stake in shares of Aratana Therapeutics in the 4th quarter valued at about $304,000. Goldman Sachs Group Inc. raised its holdings in shares of Aratana Therapeutics by 35.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 68,039 shares of the biopharmaceutical company’s stock valued at $358,000 after acquiring an additional 17,677 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Aratana Therapeutics by 11.2% in the 4th quarter. Deutsche Bank AG now owns 468,114 shares of the biopharmaceutical company’s stock valued at $2,461,000 after acquiring an additional 47,178 shares in the last quarter. 66.65% of the stock is currently owned by hedge funds and other institutional investors.
PETX stock opened at $4.93 on Wednesday. The firm has a market cap of $233.40, a PE ratio of -5.08 and a beta of 2.91. The company has a quick ratio of 2.02, a current ratio of 2.40 and a debt-to-equity ratio of 0.24. Aratana Therapeutics has a fifty-two week low of $3.67 and a fifty-two week high of $7.67.
COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.18 Per Share” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/aratana-therapeutics-inc-petx-expected-to-post-earnings-of-0-18-per-share.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.